Rockefeller Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Rockefeller Capital Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.1K	Sell	16,604 -2,200	-12%	-$9.26K	﹤0.01%	3189
2026 Q1	$78K	Buy	18,804 +1,608	+9%	+$6.53K	﹤0.01%	3015
2025 Q4	$111K	Sell	17,196 -18,309	-52%	-$114K	﹤0.01%	2670
2025 Q3	$198K	Buy	+35,505	New	+$154K	﹤0.01%	2236
2023 Q1	–	Sell	-3,166	Closed	-$2K	–	2080
2022 Q4	$2K	Hold	3,166	–	–	﹤0.01%	3539
2022 Q3	$3K	Hold	3,166	–	–	﹤0.01%	3459
2022 Q2	$2K	Hold	3,166	–	–	﹤0.01%	3746
2022 Q1	$8K	Hold	3,166	–	–	﹤0.01%	3142
2021 Q4	$12K	Hold	3,166	–	–	﹤0.01%	2872
2021 Q3	$13K	Hold	3,166	–	–	﹤0.01%	2755
2021 Q2	$12K	Hold	3,166	–	–	﹤0.01%	2693
2021 Q1	$16K	Buy	3,166 +964	+44%	+$5.13K	﹤0.01%	2369
2020 Q4	$11K	Sell	2,202 -1,818	-45%	-$10.9K	﹤0.01%	2195
2020 Q3	$19K	Buy	+4,020	New	+$26.3K	﹤0.01%	1799

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Rockefeller Capital Management's AQST Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Aquestive Therapeutics (AQST) stake by 12% in Q2 2026, selling an estimated $9.26K and leaving 16,604 shares worth $69.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Rockefeller Capital Management first reported a position in AQST in Q3 2020 and has held it in 14 quarters since. The position peaked at $198K in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Rockefeller Capital Management held 16,604 shares of Aquestive Therapeutics worth $69.1K as of Q2 2026.
Rockefeller Capital Management sold 2,200 Aquestive Therapeutics shares in Q2 2026, an estimated $9.26K.
Aquestive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3189 holding.
Rockefeller Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 14 quarters since.
Rockefeller Capital Management's Aquestive Therapeutics position peaked at $198K in Q3 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.